Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Brolucizumab→

Brolucizumab Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1531589-13-5
Molecular formula
C1164H1768N310O372S8
Molecular weight
26312.88 g/mol
Drug class
Humanised monoclonal antibody fragment (scFv)vascular endothelial growth factor A (VEGF-A) inhibitor
Mechanism of action
Binds VEGF-A isoforms and prevents their interaction with VEGF receptors, reducing endothelial-cell proliferation, neovascularisation and vascular permeability in the retina.
Indications / reported uses
  • Treatment of neovascular (wet) age-related macular degeneration (nAMD) in adults
  • Treatment of diabetic macular oedema (DME) in adults where authorised by the relevant product label

Sources: US FDA prescribing information — BEOVU · EMA EPAR — Beovu · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Brolucizumab Environmental Risk Assessment (ERA) (the Brolucizumab ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.